206 related articles for article (PubMed ID: 15627209)
1. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.
Krüger T; Schoor O; Lemmel C; Kraemer B; Reichle C; Dengjel J; Weinschenk T; Müller M; Hennenlotter J; Stenzl A; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2005 Sep; 54(9):826-36. PubMed ID: 15627209
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
Seliger B; Dressler SP; Massa C; Recktenwald CV; Altenberend F; Bukur J; Marincola FM; Wang E; Stevanovic S; Lichtenfels R
Proteomics; 2011 Jun; 11(12):2528-41. PubMed ID: 21595034
[TBL] [Abstract][Full Text] [Related]
3. HLA ligand profiles of primary renal cell carcinoma maintained in metastases.
Stickel JS; Weinzierl AO; Hillen N; Drews O; Schuler MM; Hennenlotter J; Wernet D; Müller CA; Stenzl A; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2009 Sep; 58(9):1407-17. PubMed ID: 19184600
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
5. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
6. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.
Krämer BF; Schoor O; Krüger T; Reichle C; Müller M; Weinschenk T; Hennenlotter J; Stenzl A; Rammensee HG; Stevanovic S
Cancer Biol Ther; 2005 Sep; 4(9):943-8. PubMed ID: 16082191
[TBL] [Abstract][Full Text] [Related]
7. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
8. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
9. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.
Dengjel J; Nastke MD; Gouttefangeas C; Gitsioudis G; Schoor O; Altenberend F; Müller M; Krämer B; Missiou A; Sauter M; Hennenlotter J; Wernet D; Stenzl A; Rammensee HG; Klingel K; Stevanović S
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4163-70. PubMed ID: 16857787
[TBL] [Abstract][Full Text] [Related]
10. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
Dörrschuck A; Schmidt A; Schnürer E; Glückmann M; Albrecht C; Wölfel C; Lennerz V; Lifke A; Di Natale C; Ranieri E; Gesualdo L; Huber C; Karas M; Wölfel T; Herr W
Blood; 2004 Oct; 104(8):2591-9. PubMed ID: 15231579
[TBL] [Abstract][Full Text] [Related]
11. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
12. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
Sato E; Torigoe T; Hirohashi Y; Kitamura H; Tanaka T; Honma I; Asanuma H; Harada K; Takasu H; Masumori N; Ito N; Hasegawa T; Tsukamoto T; Sato N
Clin Cancer Res; 2008 Nov; 14(21):6916-23. PubMed ID: 18980986
[TBL] [Abstract][Full Text] [Related]
13. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
[TBL] [Abstract][Full Text] [Related]
14. Structure, expression and function of HLA-G in renal cell carcinoma.
Seliger B; Schlaf G
Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
[TBL] [Abstract][Full Text] [Related]
15. Integrated functional genomics approach for the design of patient-individual antitumor vaccines.
Weinschenk T; Gouttefangeas C; Schirle M; Obermayr F; Walter S; Schoor O; Kurek R; Loeser W; Bichler KH; Wernet D; Stevanović S; Rammensee HG
Cancer Res; 2002 Oct; 62(20):5818-27. PubMed ID: 12384544
[TBL] [Abstract][Full Text] [Related]
16. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
17. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response.
Bukur J; Malenica B; Huber C; Seliger B
Hum Immunol; 2003 Nov; 64(11):1081-92. PubMed ID: 14602239
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
20. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
